Scotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)
Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00. The company’s shares opened today at $9.06.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Farmer is an analyst with an average return of -4.3% and a 38.95% success rate. Farmer covers the Healthcare sector, focusing on stocks such as Urogen Pharma, Tempest Therapeutics, and Adaptimmune Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for SAGE Therapeutics with a $8.88 average price target.
Based on SAGE Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $14.06 million and a GAAP net loss of $62.21 million. In comparison, last year the company earned a revenue of $7.9 million and had a GAAP net loss of $108.48 million
Read More on SAGE:
Disclaimer & DisclosureReport an Issue
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist
- Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments
- Sage Therapeutics price target raised to $8.50 from $8 at Canaccord
- Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties
